Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?

Alpha-blocking drugs, although effective antihypertensive agents, often cause tachycardia, faintness and postural hypotension. Hybrid drugs such as labetalol, which has beta- as well as alpha-blocking action, ketanserin, which has 5-hydroxytryptamine (5HT)-blocking as well as alpha-blocking action, and urapidil, which appears to have a central effect as well as an alpha-blocking action, produce fewer side effects attributable to alpha-blockade. Urapidil appears to be an effective antihypertensive drug with a wide spectrum of action and few side effects.